GlassScriptPhysician profile
Leo Treyzon
NPI 1740304203
$18,891.18
in general payments reported to CMS, 2019-2025
44 companies · $3,627 in 2025
The $3,627 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $1,465 · 2021: $2,258 · 2022: $3,218 · 2023: $3,055 · 2024: $3,081 · 2025: $3,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,602 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,601.58 |
| Education | $160.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,071.57 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $3,784.70 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,705.57 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,544.96 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $1,305.97 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $730.16 | 2021-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $477.90 | 2021-2023 | |
| Daiichi Sankyo INC. | $473.79 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $434.65 | 2020-2025 | Linzess |
| Aimmune Therapeutics, INC. | $368.89 | 2024-2025 | Vowst, Zenpep |
| Phathom Pharmaceuticals, INC. | $311.22 | 2024-2025 | Voquezna |
| Pfizer INC. | $287.73 | 2019-2022 | |
| Romark Laboratories, Lc | $287.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $271.30 | 2022-2025 | Dupixent |
| Celgene Corporation | $241.21 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $227.17 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $224.38 | 2019-2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $177.29 | 2019-2024 | |
| Genzyme Corporation | $175.08 | 2022-2025 | |
| Redhill Biopharma INC. | $165.07 | 2020-2024 | Talicia |
| Alnylam Pharmaceuticals INC. | $162.03 | 2022-2025 | Givlaari, Oxlumo |
| Conmed Corporation | $152.79 | 2023 | Conmed Biliary |
| Boston Scientific Corporation | $137.54 | 2019-2022 | |
| Exact Sciences Corporation | $125.42 | 2023-2025 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $120.32 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.61 | 2021 | |
| Allergan, INC. | $105.75 | 2019-2020 | |
| Pharming Healthcare, INC. | $105.51 | 2019 | |
| Alfasigma USA, INC. | $68.36 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $67.89 | 2020-2023 | Rebyota |
| Vivus LLC | $64.58 | 2023-2025 | Pancreaze |
| Lilly USA, LLC | $53.27 | 2025 | Zepbound, Mounjaro |
| Biofire Diagnostics, LLC | $50.45 | 2019-2020 | |
| Shionogi INC | $43.96 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $40.18 | 2019 | |
| Amgen INC. | $34.78 | 2022 | |
| Alexion Pharmaceuticals, INC. | $33.85 | 2022 | |
| Lucid Diagnostics INC. | $25.02 | 2022 | |
| Digestive Care, INC. | $23.35 | 2025 | Pertzye |
| Evoke Pharma, INC. | $21.66 | 2020 | |
| Blueprint Medicines Corporation | $20.70 | 2023 | |
| Novo Nordisk INC | $20.37 | 2025 | Wegovy |
| Concordia Pharmaceuticals INC. | $20.00 | 2019 | |
| Medtronic, INC. | $15.64 | 2023 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Treyzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.